NBIX

#764
Neurocrine Biosciences Inc
130.3450 USD
+3.19%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
130.1600
130.6950
Rango anual
122.1375
160.1800
Cambio diario
+3.19%
Variación mensual
-0.04%
Variación en los últimos 6 meses
-10.11%
Cambio anual
-10.11%
Cierres anteriores
126.3200
Abrir
130.3250
Bid
Ask
Mínimo
130.1600
High
130.6950
Volumen
66
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 13.0819 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
30.37
Relación precio/flujo de caja
5.08

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Noticias